Read the Patient Information Leaflet and Instructions for Use if available from your pharmacist before you start using immune globulin and each time you get a refill. If you have any questions ...

This approval introduces the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy in Japan, offering patients a new treatment option. HYQVIA combines subcutaneous immunoglobulin ...

The approval marks availability of the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy as a treatment option for appropriate patients in Japan. HYQVIA is the first plasma ...

Analysts have recently evaluated KORU Medical Systems and provided 12-month price targets. The average target is $4.7, ...

Innovative Health Sciences has successfully secured the exclusive Medical Device Regulations Quality Management System ...

Takeda's HYQVIA is the first facilitated subcutaneous immunoglobulin therapy approved in Japan for agammaglobulinemia. HYQVIA offers less frequent dosing (every 3-4 weeks), improving patient ...

HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the First and Only Facilitated Subcutaneous Immunoglobulin (fSCIG) Approved in Japan for Agammaglobulinemia ...

The approval marks availability of the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy as a treatment option for appropriate patients in Japan. HYQVIA is the first ...